No new COVID-19 cases involving the omicron coronavirus variant were reported in Minnesota on Monday, but the dominant delta variant was creating plenty of problems for the state.
COVID-19 hospitalizations in Minnesota increased to 1,570 on Friday, including 346 people receiving intensive care. The state reported a 98% occupancy rate of adult intensive care beds when including COVID and non-COVID patients, the highest in the pandemic.
Minnesotans can reduce the burden by getting COVID-19 vaccines and boosters and by limiting chances for viral exposure in gatherings and crowds, said Dr. Andrew Olson, a hospitalist and leader of the COVID-19 response for M Health Fairview. Among the 307 COVID-19 patients in the system's hospitals, 72% are unvaccinated.
"I think that life can go on," he said, "but life can't go on pretending that nothing is going on."
Minnesota leaders are watching closely for signs of a COVID-19 surge as a result of viral spread over Thanksgiving. The state's reported positivity rate of COVID-19 diagnostic testing increased for the first time in two weeks to 10.4%, keeping it above the 10% high-risk threshold for substantial viral spread. However, the rate dates back to the seven-day period ending Nov. 26, so the holiday's impact remains unclear.
The state also is monitoring for additional infections involving omicron, which was labeled a variant of concern after it was identified in South Africa because of its rapid spread and its potential ability to evade immunity from previous infection or vaccination.
"We don't yet know what impact this will have on the pandemic," said Dr. Andrew Badley, an infectious disease specialist leading Mayo Clinic's COVID-19 research task force, on Monday. "There are some reports that the disease penetration is lower with the omicron variant, meaning that people get less from it. If that's true, that's a very good thing."
On the other hand, omicron could produce so many infections that it results in more hospitalizations even if the rate of severe illness is lower, he said. Monoclonal antibody therapies might not work as well against omicron infections, though Badley said they will likely offer some benefit.